MAAT MaaT Pharma SA

0.9542USD0.8700 EUR · EPA-3.55%Mkt Cap: 17.96M USDP/E: —

MaaT Pharma SA, a late-stage clinical company, engages in the development of gut microbiome-driven therapies to modulate the immune system and improve cancer survival. Its products pipeline includes MaaT013, that is in p…

Institutional holders2 on file

Key Statistics

Company
Market Cap17.96M USD
Enterprise Value25.31M USD
Revenue (TTM)3.48M USD
Gross Profit3.43M USD
Net Income (TTM)-34.07M USD
Revenue/Share0.20 USD
Last Price0.9542 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees60
CountryFR
SectorHealthcare
IndustryBiotechnology
ISINFR0012634822
Valuation
P/E (Trailing)—
P/E (Forward)-0.90
PEG—
EV/EBITDA-0.75
EV/Revenue7.27
P/S5.16
P/B-1.01
EPS (TTM)-2.28 USD
EPS (Forward)-1.06 USD
52W Range
0.95420% of range9.454
52W High9.454 USD
52W Low0.9542 USD
Profitability
Gross Margin69.05%
Oper. Margin-1069.99%
EBITDA Margin0.00%
Profit Margin-686.58%
ROE-1726.57%
ROA-69.72%
ROIC—
ROCE-107.82%
Growth
Revenue Growth-55.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-17.24M USD
CapEx (TTM)666.85K USD
FCF Margin-108.89%
FCF Yield-21.12%
Net Debt7.32M USD
Net Debt/EBITDA-0.22
Net Debt/FCF—
Balance Sheet
Debt/Equity8.56
Current Ratio1.36
Quick Ratio1.26
Book Value/Sh-0.94 USD
Cash/Share0.99 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.0 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)3.290 USD
Upside (mean)+244.8%
Target Range3.290 USD – 3.290 USD
# Analysts1
Ownership
Shares Out.18.82M
Float11.05M
Insiders22.06%
Institutions46.78%
Technical
SMA 501.304 (-26.8%)
SMA 2004.082 (-76.6%)
Beta0.62
S&P 52W Chg12.00%
Avg Vol (30d)80.66K
Avg Vol (10d)95.86K
Technical Indicators
RSI (14)28.8
MACD-0.0712
MACD Signal-0.0749
MACD Hist.+0.0037
BB Upper1.257 USD
BB Middle1.131 USD
BB Lower1.004 USD
BB Width22.37%
ATR (14)0.0862 USD
Vol Ratio (20d)1.04x

About MaaT Pharma (EPA: MAAT)

›

MaaT Pharma (EPA: MAAT) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 60 employees.

The shares were at 0.8700 EUR on 19 November 2026, down 77.9% over 52 weeks. Its 52-week range is 0.8700 EUR to 8.620 EUR, and it trades at the bottom of that range.

Its market capitalisation is 16.38M EUR.

MaaT Pharma reports revenue down 55.5% year over year.

Its debt exceeds its cash by 6.67M EUR, a debt-to-equity ratio of 8.56. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. One analyst covers the stock, with an average rating of Buy; their mean price target of 3.000 EUR is 244.8% above the current price.